Corvidia Therapeutics Inc., a leading clinical stage biotechnology company, will present its work on an investigational cardio-renal therapy being developed to address residual inflammatory cardiovascular risk in patients living with Chronic Kidney Disease (CKD) at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco next week.
More:
prnewswire.com/news-releases/corvidia-therapeutics-to-present-on-novel-anti-inflammatory-therapy-for-cardio-renal-disease-at-jp-morgan-healthcare-conference-300773247.html
More:
prnewswire.com/news-releases/corvidia-therapeutics-to-present-on-novel-anti-inflammatory-therapy-for-cardio-renal-disease-at-jp-morgan-healthcare-conference-300773247.html
No comments:
Post a Comment